Cord blood CD34+ cells cultured with FLT3L, stem cell factor, interleukin-6, and IL-3 produce CD11c+CD1a-/c- myeloid dendritic cells

S Fadilah S. Abdul Wahid, S. Vuckovic, D. Khalil, D. N J Hart

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Methods that allow expansion of myeloid dendritic cells (MDCs) from CD34+ cells are potentially important for boosting anti-leukemic responses after cord blood (CB) hematopoietic stem cell transplantation (HSCT). We showed that the combination of early-acting cytokines FLT3-ligand (FL), stem cell factor (SCF), interleukin (IL)-3, and IL-6 supported the generation of CD11c+CD16- CD1a-/c- MDCs from CB CD34+ cells or CB myeloid precursors. Early-acting cytokine-derived MDCs were maintained within the myeloid CD33+CD14 -CD15- precursors with a mean of 4 × 106 cells generated from 1-4 × 104 CB CD34+ cells or myeloid precursors after 2 weeks. After 8-12 days of culture the MDCs expressed higher levels of HLA-DR antigen but lower levels of CD40 and CD86 antigen, compared to adult blood MDCs. At this stage of differentiation, the early-acting cytokine-derived MDCs had acquired the ability to induce greater allogeneic T cell proliferation than monocytes or granulocytes derived from same culture. Early-acting cytokine-derived MDCs exposed to the cytokine cocktail (CC) comprising IL-1β, IL-6, tumor necrosis factor (TNF)-α, and prostaglandin E (PGE)-2, upregulated the surface co-stimulatory molecules CD40 and CD86 and enhanced allogeneic T cell proliferation, as is characteristic of MDCs maturation. The reliable production of MDCs from CB CD34+ cells provides a novel way to study their lineage commitment pathway(s) and also a potential means of enriching CB with MDCs to improve prospects for DC immunotherapy following CB HSCT.

Original languageEnglish
Pages (from-to)849-855
Number of pages7
JournalStem Cells and Development
Volume16
Issue number5
DOIs
Publication statusPublished - 1 Oct 2007

Fingerprint

Stem Cell Factor
Interleukin-3
Myeloid Cells
Fetal Blood
Dendritic Cells
Interleukin-6
Blood Cells
Cytokines
Cord Blood Stem Cell Transplantation
Hematopoietic Stem Cell Transplantation
CD40 Antigens
CD86 Antigens
Cell Proliferation
T-Lymphocytes
HLA-DR Antigens
Prostaglandins E
Interleukin-1
Granulocytes
Immunotherapy
Monocytes

ASJC Scopus subject areas

  • Hematology

Cite this

Cord blood CD34+ cells cultured with FLT3L, stem cell factor, interleukin-6, and IL-3 produce CD11c+CD1a-/c- myeloid dendritic cells. / S. Abdul Wahid, S Fadilah; Vuckovic, S.; Khalil, D.; Hart, D. N J.

In: Stem Cells and Development, Vol. 16, No. 5, 01.10.2007, p. 849-855.

Research output: Contribution to journalArticle

@article{8cae2708e0384d0fb65295dbf2aac200,
title = "Cord blood CD34+ cells cultured with FLT3L, stem cell factor, interleukin-6, and IL-3 produce CD11c+CD1a-/c- myeloid dendritic cells",
abstract = "Methods that allow expansion of myeloid dendritic cells (MDCs) from CD34+ cells are potentially important for boosting anti-leukemic responses after cord blood (CB) hematopoietic stem cell transplantation (HSCT). We showed that the combination of early-acting cytokines FLT3-ligand (FL), stem cell factor (SCF), interleukin (IL)-3, and IL-6 supported the generation of CD11c+CD16- CD1a-/c- MDCs from CB CD34+ cells or CB myeloid precursors. Early-acting cytokine-derived MDCs were maintained within the myeloid CD33+CD14 -CD15- precursors with a mean of 4 × 106 cells generated from 1-4 × 104 CB CD34+ cells or myeloid precursors after 2 weeks. After 8-12 days of culture the MDCs expressed higher levels of HLA-DR antigen but lower levels of CD40 and CD86 antigen, compared to adult blood MDCs. At this stage of differentiation, the early-acting cytokine-derived MDCs had acquired the ability to induce greater allogeneic T cell proliferation than monocytes or granulocytes derived from same culture. Early-acting cytokine-derived MDCs exposed to the cytokine cocktail (CC) comprising IL-1β, IL-6, tumor necrosis factor (TNF)-α, and prostaglandin E (PGE)-2, upregulated the surface co-stimulatory molecules CD40 and CD86 and enhanced allogeneic T cell proliferation, as is characteristic of MDCs maturation. The reliable production of MDCs from CB CD34+ cells provides a novel way to study their lineage commitment pathway(s) and also a potential means of enriching CB with MDCs to improve prospects for DC immunotherapy following CB HSCT.",
author = "{S. Abdul Wahid}, {S Fadilah} and S. Vuckovic and D. Khalil and Hart, {D. N J}",
year = "2007",
month = "10",
day = "1",
doi = "10.1089/scd.2007.0003",
language = "English",
volume = "16",
pages = "849--855",
journal = "Stem Cells and Development",
issn = "1547-3287",
publisher = "Mary Ann Liebert Inc.",
number = "5",

}

TY - JOUR

T1 - Cord blood CD34+ cells cultured with FLT3L, stem cell factor, interleukin-6, and IL-3 produce CD11c+CD1a-/c- myeloid dendritic cells

AU - S. Abdul Wahid, S Fadilah

AU - Vuckovic, S.

AU - Khalil, D.

AU - Hart, D. N J

PY - 2007/10/1

Y1 - 2007/10/1

N2 - Methods that allow expansion of myeloid dendritic cells (MDCs) from CD34+ cells are potentially important for boosting anti-leukemic responses after cord blood (CB) hematopoietic stem cell transplantation (HSCT). We showed that the combination of early-acting cytokines FLT3-ligand (FL), stem cell factor (SCF), interleukin (IL)-3, and IL-6 supported the generation of CD11c+CD16- CD1a-/c- MDCs from CB CD34+ cells or CB myeloid precursors. Early-acting cytokine-derived MDCs were maintained within the myeloid CD33+CD14 -CD15- precursors with a mean of 4 × 106 cells generated from 1-4 × 104 CB CD34+ cells or myeloid precursors after 2 weeks. After 8-12 days of culture the MDCs expressed higher levels of HLA-DR antigen but lower levels of CD40 and CD86 antigen, compared to adult blood MDCs. At this stage of differentiation, the early-acting cytokine-derived MDCs had acquired the ability to induce greater allogeneic T cell proliferation than monocytes or granulocytes derived from same culture. Early-acting cytokine-derived MDCs exposed to the cytokine cocktail (CC) comprising IL-1β, IL-6, tumor necrosis factor (TNF)-α, and prostaglandin E (PGE)-2, upregulated the surface co-stimulatory molecules CD40 and CD86 and enhanced allogeneic T cell proliferation, as is characteristic of MDCs maturation. The reliable production of MDCs from CB CD34+ cells provides a novel way to study their lineage commitment pathway(s) and also a potential means of enriching CB with MDCs to improve prospects for DC immunotherapy following CB HSCT.

AB - Methods that allow expansion of myeloid dendritic cells (MDCs) from CD34+ cells are potentially important for boosting anti-leukemic responses after cord blood (CB) hematopoietic stem cell transplantation (HSCT). We showed that the combination of early-acting cytokines FLT3-ligand (FL), stem cell factor (SCF), interleukin (IL)-3, and IL-6 supported the generation of CD11c+CD16- CD1a-/c- MDCs from CB CD34+ cells or CB myeloid precursors. Early-acting cytokine-derived MDCs were maintained within the myeloid CD33+CD14 -CD15- precursors with a mean of 4 × 106 cells generated from 1-4 × 104 CB CD34+ cells or myeloid precursors after 2 weeks. After 8-12 days of culture the MDCs expressed higher levels of HLA-DR antigen but lower levels of CD40 and CD86 antigen, compared to adult blood MDCs. At this stage of differentiation, the early-acting cytokine-derived MDCs had acquired the ability to induce greater allogeneic T cell proliferation than monocytes or granulocytes derived from same culture. Early-acting cytokine-derived MDCs exposed to the cytokine cocktail (CC) comprising IL-1β, IL-6, tumor necrosis factor (TNF)-α, and prostaglandin E (PGE)-2, upregulated the surface co-stimulatory molecules CD40 and CD86 and enhanced allogeneic T cell proliferation, as is characteristic of MDCs maturation. The reliable production of MDCs from CB CD34+ cells provides a novel way to study their lineage commitment pathway(s) and also a potential means of enriching CB with MDCs to improve prospects for DC immunotherapy following CB HSCT.

UR - http://www.scopus.com/inward/record.url?scp=36248974252&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=36248974252&partnerID=8YFLogxK

U2 - 10.1089/scd.2007.0003

DO - 10.1089/scd.2007.0003

M3 - Article

C2 - 17999605

AN - SCOPUS:36248974252

VL - 16

SP - 849

EP - 855

JO - Stem Cells and Development

JF - Stem Cells and Development

SN - 1547-3287

IS - 5

ER -